Lupin Ltd.
Clinical trials sponsored by Lupin Ltd., explained in plain language.
Global pharmaceutical company producing generic and branded medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for muscle stiffness: Once-Daily pill tested in myotonic dystrophy
Symptom relief Recruiting nowThis Phase 3 trial tests whether a once-daily dose of mexiletine PR can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 participants will receive either the drug or a placebo for 26 weeks. The main measure is how quickly hand m…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New study tests safer version of muscle stiffness drug
Symptom relief Recruiting nowThis study tests a new extended-release form of mexiletine (mexiletine PR) against the standard immediate-release version in people with non-dystrophic myotonias, a group of rare genetic disorders that cause muscle stiffness. About 24 adults aged 16 and older will take each versi…
Phase: PHASE3 • Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
New registry tracks safety of mexiletine in kids with myotonia
Symptom relief Recruiting nowThis study follows up to 10 children from birth to under 6 years old who have genetic muscle disorders causing stiffness (myotonia) and are taking mexiletine. Researchers will collect data on side effects and how the medicine is used in routine care over the long term. The goal i…
Sponsor: Lupin Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC